Regeneron Pharmaceuticals announced promising results from the Phase 3 C-POST trial of Libtayo (cemiplimab), a PD-1 inhibitor for patients with high-risk cutaneous squamous cell carcinoma (CSCC) ...

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: ...

Libtayo showed similar SPT rates to placebo but improved DFS in high-risk CSCC patients post-surgery and radiotherapy. The C-POST trial demonstrated Libtayo's superior DFS rates, with 81.1% at 24 ...

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of ...

Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo. The Food and Drug Administration (FDA) has approved Libtayo ® (cemiplimab-rwlc) for the ...

TARRYTOWN, N.Y., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from the Phase 3 C-POST trial, which demonstrated that adjuvant ...

Regeneron has fleshed out additional positive data for blockbuster immunotherapy Libtayo (cemiplimab) as an adjuvant therapy in high-risk cutaneous squamous cell carcinoma (CSCC), as rival PD-1 ...

TARRYTOWN, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data from its oncology and hematology portfolio will be shared at the ...